March 16, 2026
Reporter, Health Care Inc. Writer
A full-year subscription to STAT is currently half off — half off! Your journalistic conscience will be full. Sounds like a solid deal to me. If you’re looking for something to do for free, forward this newsletter to a friend. Or you can always send me an email from the park or something: bob.herman@statnews.com.

in the courts

Leapfrogging around

One of the most interesting health care legal cases right now pits a prominent nonprofit that rates hospital quality against a handful of for-profit hospitals in Florida. And there’s no clear angel, my colleague Tara Bannow reports.

A federal judge recently said The Leapfrog Group violated Florida’s consumer protection law by unfairly penalizing five Tenet Healthcare hospitals that didn’t take its surveys. Leapfrog now has to withdraw its ratings on those hospitals and change its methodology for rating them. Leapfrog is appealing, and the group’s CEO, Leah Binder, says this is a matter of protecting the First Amendment for anyone who produces public ratings. 

However, after Tara talked with several experts and both parties, “neither Leapfrog nor the hospitals emerged from the case looking stellar,” she writes. Consumer protection laws aren’t supposed to protect the entities that are selling products and services (in this case, the Tenet hospitals). But Leapfrog also appeared to penalize hospitals that don’t take its surveys — calling itself a “Disney villain” in documents that came out during the case. And Leapfrog has a clear financial stake in this since it makes money from the results of those surveys. Read more from Tara, which includes a fun kicker.


cms

Medicaid still going commercial

The Centers for Medicare and Medicaid Services continues to approve billions in new Medicaid funding, allowing hospitals and other clinical groups to get paid much higher commercial prices for Medicaid patients.

We’ve been tracking these so-called state directed payment programs for the past year. They are especially important to hospitals right now because President Trump’s One Big Beautiful Bill Act will start to cut these arrangements in 2028. 

The newest Medicaid approvals: $2.3 billion in Wisconsin and $1.9 billion in Georgia. A report from Preston Mizell of Fox News also said a $7.8 billion state directed program in Florida has gotten clearance, although CMS has not publicly posted the approval.


unitedhealth

Discovery zone

After months of stalling, UnitedHealth Group will have to fork over reams of internal documents that detail how it used artificial intelligence in the care of Medicare patients, a judge ruled last week.

In 2023, the family members of deceased Medicare Advantage enrollees filed a class action lawsuit against UnitedHealth, claiming the company’s technology systematically denied nursing home care in violation of Medicare law. This lawsuit stemmed from the investigative series from my colleague Casey Ross and me that found UnitedHealth relied on an algorithm, called nH Predict, to end rehab care prematurely for sick and injured seniors as a way to save money.

A judge said the case could proceed in February 2025, but the two sides have been locked in a feud over what information UnitedHealth had to hand over during the discovery process. The newest order will force UnitedHealth to hand over a vast majority of what the plaintiffs wanted, including all the names and information of UnitedHealth’s internal “AI review board,” documents showing how NaviHealth employees were trained and assessed on the use of nH Predict, documents related to UnitedHealth’s acquisition of NaviHealth, and the identities of all employees who issued Medicare denials. UnitedHealth has until March 30 to produce the documents.



medicare advantage

Tempering intensity

Screenshot 2026-03-12 at 3.21.54 PMMedicare Payment Advisory Commission

If Medicare Advantage enrollees were instead in traditional Medicare, the government would be paying $76 billion less this year, the Medicare Payment Advisory Commission said in its official March report issued to Congress.

While that amount of overpayments has stayed above $75 billion each year since 2023, the factors behind them are shifting. “Coding intensity” — how aggressively Medicare Advantage insurers code their members’ health conditions, as a way to get paid more — is less of a factor in those overpayments now. That’s because the government has completed the three-year phase-in of a new system that pays for those diagnoses. The bigger factor now: “favorable selection,” which describes how healthier-than-average people are coming into Medicare Advantage and require less care. Read more from me about MedPAC (and how industry groups are trying to sink faith in the group).


hospitals

The sound of silence

Many hospitals (not all) have hated the idea of site-neutral payments. This wonky policy has a simple end goal: Services provided in a hospital-owned clinic and an independent physician clinic should be the same. But hospitals haven’t made much noise about a new policy that would do that in a limited way.

Starting this year, Medicare will equalize payments between hospitals and physician offices for a handful of “drug administration services” — like when patients get chemotherapy. Last year, Medicare paid hospitals $341 for a routine chemotherapy infusion (the service, not the drug) compared with $119 in physician offices. That payment difference now goes away. Medicare expects to save $290 million this year as a result, with $70 million pocketed by Medicare beneficiaries in coinsurance they no longer have to pay.

The American Hospital Association has previously sued over a separate, limited site-neutral policy. I asked AHA spokesperson Colin Milligan what the group was doing with this one over drug administration services, to which he responded: “No comment on our end.”


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Industry odds and ends

  • New CEO compensation numbers from 2025 continue to roll in. The latest: Dave Ricks of Eli Lilly — $103.7 million; Mike Mahoney of Boston Scientific — $57.3 million; Sam Hazen of HCA Healthcare — $34.4 million; Joaquin Duato of Johnson & Johnson — $27.9 million; David Cordani of Cigna — $24 million.
  • Autism therapy practices are feasting on Medicaid, with state Medicaid payments to autism clinics more than tripling from 2019 to 2023, according to the Wall Street Journal reporting team. Tara reported back in 2022 how private equity was rushing into autism therapy, lured by the prospect of big reimbursements.
  • The Blue Cross Blue Shield Association says it has data proving that hospitals’ use of artificial intelligence is driving up the cost of health care, my colleague Brittany Trang reports.
  • Delaware state employees who use GLP-1 drugs for weight loss will have to pay a $200 copay for a month’s supply starting July 1, up from $32, Nick Stonesifer of Spotlight Delaware reports.
  • CVS Health’s Aetna is paying nearly $118 million to settle a case that alleged the Medicare Advantage insurer knowingly submitted inaccurate diagnoses of its members to get higher payments from the government, but didn’t delete those diagnoses.
  • Related: OIG auditors found overcoding at a Medicare Advantage plan run by Blue Cross Blue Shield of Alabama. OIG said BCBS of Alabama needs to repay $7 million because one of its plans was filled with unsupported medical codes.
  • Also related: CMS is gearing up for routine “reruns” of Medicare Advantage risk scores, targeting codes that insurers submitted in 2020, 2021, and 2022, according to a recent memo.
  • This is just good writing that is both funny and poignant: Journalist Christopher Ingraham writes in Slate about his grueling cancer diagnosis — how it started as a nearly untreatable bile duct cancer and later turned out to be something else entirely.

The Meme Ward

Screenshot 2026-03-13 at 3.15.24 PM

Surely, you’ve seen “The Fugitive,” the blockbuster film from the ’90s that features Harrison Ford on the lam? Well, my colleague Alex Hogan (above, appropriately judging you if you’ve never seen it) wanted to know how STAT would have covered the central subplot of the film — pharmaceutical company Devlin MacGregor falsifying data to get its big drug approved by the FDA. He asked Allison DeAngelis, Damian Garde, Matt Herper, Lizzy Lawrence, and me to chime in for his latest STATus Report video.


Thanks for reading! More next week. 


Enjoying Health Care Inc.? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.